← Leaderboards
Monica Madden Reinholz
Mbc Research, Inc.
$733,691
Attributed
$1,267,382
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $483.1K · FY2008–10$500K$375K$250K$125K$0
'08
'09
'10
Funding mix
By agency
NIH$1,267,382 · 3
By mechanism
R01$1,067,382 · 1
R41$200,000 · 2
Top collaborators
- Edith A Perez3 shared
Others in their field
Top investigators on “Family”
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$221,216,149
- David R. Weir · University Of Michigan At Ann Arbor$166,939,143
- Richard A Gibbs · Baylor College Of Medicine$137,231,081
- Sharon A Nachman · Johns Hopkins University$135,132,510
- George R Seage · Abt Associates, Inc.$128,485,281
Research focus
FamilyFluorescent In Situ HybridizationEpidermal Growth Factor ReceptorErbb4 GeneDna Topoisomerase Ii AlphaAntibodiesDisease-Free SurvivalEnrollmentErbb2 GeneErbb3 GeneBreast Cancer TreatmentBaseCancer PatientCaringAdverse EffectsDesignAdjuvantChromosomesArtsClinical TrialsBreastCorrelative StudyCustomFollow-Up
Grant awards (5)
Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial$198,218
R01 · FY2010 · CA
Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial$483,070
R01 · FY2009 · CA
Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial$386,094
R01 · FY2008 · CA
Novel Bisphosphonates for Multiple Myeloma Therapy$100,000
R41 · FY2004 · CA
Novel Bisphosphonates for Breast Cancer Therapy$100,000
R41 · FY2002 · CA